Table 1 Patient characteristics, HSCT type, underlying disease, and immunosuppressive regimens used before HSCT
Gender | Â | n(%) |
|---|---|---|
| Â | Female | 20 (43.5) |
| Â | Male | 26 (56.5) |
Age | Â | Years (range) |
|  | Mean | 32 (18–37) |
HSCT | Â | n (%) |
| Â | Allogeneic | 31 (67.4) |
| Â | Autologous | 15 (32.6) |
Underlying disease | Â | n (%) |
| Â | Chronic myelogenous leukemia | 26 (56.5) |
| Â | Acute myelogenous leukemia | 8 (17.4) |
| Â | Multiple myeloma | 6 (13.1) |
|  | Hodgkin’s lymphoma | 3 (6.5) |
| Â | Severe aplastic anemia | 3 (6.5) |
Immunosuppressive conditioning regimen | Â | n (%) |
| Â | Busulfan and melphalan | 30 (65.2) |
| Â | Busulfan and cyclophosphamide | 4 (8.7) |
| Â | Total body irradiation and melphalan | 3 (6.5) |
| Â | Total body irradiation and cyclophosphamide | 3 (6.5) |
| Â | Other | 6 (13.1) |